Search results for "Free fatty acid"

showing 10 items of 20 documents

Pathophysiology of non alcoholic fatty liver disease

2016

The physiopathology of fatty liver and metabolic syndrome are influenced by diet, life style and inflammation, which have a major impact on the severity of the clinicopathologic outcome of non-alcoholic fatty liver disease. A short comprehensive review is provided on current knowledge of the pathophysiological interplay among major circulating effectors/mediators of fatty liver, such as circulating lipids, mediators released by adipose, muscle and liver tissues and pancreatic and gut hormones in relation to diet, exercise and inflammation.

0301 basic medicineLeptinAdipose tissueReviewDiseaseCatalysilcsh:Chemistry0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInsulinAdiponectin; Cholesterol; Fatty liver; Free fatty acids; Ghrelin; Glucagon; Glucagon-like peptide 1; Insulin; Insulin resistance; Irisin; Leptin; Selenoprotein P; Adipose Tissue; Gastrointestinal Hormones; Humans; Lipids; Muscles; Non-alcoholic Fatty Liver Disease; Pancreatic Hormones; Catalysis; Molecular Biology; Computer Science Applications1707 Computer Vision and Pattern Recognition; Spectroscopy; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic Chemistrylcsh:QH301-705.5SpectroscopyGastrointestinal HormoneFree fatty acidMusclesFatty liverComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineLipidLipidsPathophysiologyGhrelinComputer Science ApplicationsCholesterolAdipose TissueMuscleAdiponectinmedicine.symptomHumanmedicine.medical_specialtyIrisinSettore MED/12 - GASTROENTEROLOGIA030209 endocrinology & metabolismInflammationBiologyFree fatty acidsCatalysisPancreatic HormoneGastrointestinal HormonesInorganic Chemistry03 medical and health sciencesInternal medicineFatty liverSelenoprotein PmedicineHumansPhysical and Theoretical ChemistryGlucagon-like peptide 1Molecular BiologyOrganic ChemistryNon alcoholicInsulin resistancemedicine.diseaseGut hormonesGlucagonPancreatic Hormones030104 developmental biologyEndocrinologylcsh:Biology (General)lcsh:QD1-999Metabolic syndrome
researchProduct

Lipidomics reveals altered biosynthetic pathways of glycerophospholipids and cell signaling as biomarkers of the polycystic ovary syndrome

2017

// Mariona Jove 1, * , Irene Pradas 1, * , Alba Naudi 1, * , Susana Rovira-Llopis 2 , Celia Banuls 2 , Milagros Rocha 2 , Manuel Portero-Otin 1 , Antonio Hernandez-Mijares 2, 3, 4, # , Victor M. Victor 2, 5, # and Reinald Pamplona 1, # 1 Department of Experimental Medicine, Lleida University-Institute for Research in Biomedicine of Lleida (UdL-IRBLleida), 25198 Lleida, Spain 2 Foundation for the Promotion of Healthcare and Biomedical Research in the Valencian Community (FISABIO), Service of Endocrinology, University Hospital Dr. Peset, 46017 Valencia, Spain 3 Fundacion Investigacion Hospital Clinico Universitario/INCLIVA, Valencia University, 46010 Valencia, Spain 4 Department of Medicine, …

0301 basic medicineOncologyCell signaling moleculesmedicine.medical_specialtyCell signalingGlycerophospholipidsDiseaseGlycerophospholipidsFree fatty acidsValencian community03 medical and health sciences0302 clinical medicineInternal medicineLipidomicsmedicinelipid de novo biosynthesisglycerophospholipids030219 obstetrics & reproductive medicinebusiness.industryfree fatty acidsLipidomeUniversity hospitalPolycystic ovary030104 developmental biologyOncologyLipidomicscell signaling moleculeslipidomicsbusinessResearch PaperOncotarget
researchProduct

Decreases in Circulating Concentrations of Long-Chain Acylcarnitines and Free Fatty Acids During the Glucose Tolerance Test Represent Tissue-Specific…

2019

Background: Insulin plays a pivotal role in the regulation of both carbohydrate and lipid intermediate turnover and metabolism. In the transition from a fasted to fed state, insulin action inhibits lipolysis in adipocytes, and acylcarnitine synthesis in the muscles and heart. The aim of this study was to measure free fatty acid (FFA) and acylcarnitine levels during the glucose tolerance test as indicators of tissue-specific insulin resistance. Results: Insulin release in response to glucose administration decreased both FFA and long-chain acylcarnitine levels in plasma in healthy control animals by 30% (120 min). The glucose tolerance test and [3H]-deoxy-D-glucose uptake in tissues revealed…

0301 basic medicinemedicine.medical_specialtyGlucose uptakemedicine.medical_treatmentEndocrinology Diabetes and MetabolismAdipose tissuelong-chain acylcarnitines030209 endocrinology & metabolismType 2 diabetesglucose tolerance testlcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health sciences0302 clinical medicineInsulin resistanceEndocrinologyInternal medicineinsulin resistancemedicineLipolysisOriginal ResearchGlucose tolerance testlcsh:RC648-665medicine.diagnostic_testChemistryInsulinfree fatty acidsmedicine.disease030104 developmental biologyEndocrinologyPostprandialtype 2 diabetesFrontiers in Endocrinology
researchProduct

9-cis-Retinoic acid enhances fatty acid-induced expression of the liver fatty acid-binding protein gene

1997

The role of retinoic acids (RA) on liver fatty acid- binding protein (L-FABP) expression was investigated in the well differentiated FAO rat hepatoma cell line. 9-cis-Retinoic acid (9-ci's-RA) specifically enhanced L-FABP mRNA levels in a time- and dose-dependent manner. The higher induction was found 6 h after addition of 10 -6 M 9-CK-RA in the medium. RA also enhanced further both L-FABP mRNA levels and cytosolic L-FABP protein content induced by oleic acid. The retinoid X receptor (RXR) and the peroxisome proliferator-activated receptor (PPAR), which are known to be activated, respectively, by 9-c/s-RA and long chain fatty acid (LCFA), co-operated to bind specifically the peroxisome prol…

9-cw-Retinoic acidReceptors Retinoic Acid[SDV]Life Sciences [q-bio]Receptors Cytoplasmic and NuclearPeroxisome proliferator-activated receptorMyelin P2 ProteinMicrobodiesBiochemistry0302 clinical medicineStructural BiologyTumor Cells CulturedAlitretinoinchemistry.chemical_classification0303 health sciencesChemistryFatty AcidsDrug SynergismPeroxisomeNeoplasm Proteins9-cis-Retinoic acidLiverBiochemistryFree fatty acid receptorlipids (amino acids peptides and proteins)Peroxisome proliferator-activated receptor alphaLong chain fatty acidFatty Acid-Binding Protein 7DimerizationPeroxisome proliferator-activated receptor gammaCarcinoma HepatocellularBiophysicsNerve Tissue ProteinsTretinoinRetinoid X receptorFatty Acid-Binding ProteinsLiver fatty acid-binding protein03 medical and health sciencesGeneticsAnimalsRNA MessengerMolecular Biology030304 developmental biologyFAO hepatoma cellFatty acidCell BiologyFatty acidRatsRetinoid X ReceptorsGene Expression RegulationNuclear receptorGene expressionCarrier Proteins[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition030217 neurology & neurosurgeryTranscription FactorsFEBS Letters
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration

2004

Background: Hyperinsulinemia/insulin resistance and elevated plasma free fatty acids (FFA) levels are involved in the hypertension and cardiac sympathetic overactivity. Metformin improves insulin action and lower plasma FFA concentrations. We investigate the possible effect of metformin on arterial blood pressure (BP) and cardiac sympathetic nervous system. Methods: One hundred twenty overweight type 2 diabetic patients were treated by placebo (n = 60) + diet or metformin (850 mg twice daily) (n = 60) + diet for 4 months, to evaluate the effect of metformin treatment on the cardiac autonomic nervous system. Insulin resistance was measured by the Homeostasis Model Assessment (HOMA) index. He…

Blood GlucoseMalemedicine.medical_specialtyendocrine system diseasesmedicine.medical_treatmentBlood PressureType 2 diabetesFatty Acids NonesterifiedAutonomic Nervous SystemInsulin resistanceHeart RateDiabetes mellitusInternal medicineInternal MedicineHyperinsulinemiaDiabetes MellitusMedicineHumansHypoglycemic AgentsObesityHeart rate variabilityTriglyceridesAgedGlycated HemoglobinFree fatty acidAnthropometrybusiness.industryInsulinnutritional and metabolic diseasesInsulin resistanceMiddle Agedmedicine.diseaseMetforminMetforminEndocrinologyBlood pressureTreatment OutcomeDiabetes Mellitus Type 2Multivariate AnalysisFemalebusinessHyperinsulinismBiomarkersmedicine.drug
researchProduct

Ketogenic diet as antiepileptic therapy: Historical perspective

2017

Ketogenic diet (KD) is a high-lipid diet, adequate for protein content but low in carbohydrates content. Caloric intake is calculated on the basis of the ideal patient's needs, reduced by about 20%, and is about 90% of lipids present in 3: 1 or 4: 1 ratio with proteins and carbohydrates. KD is considered the most ancient antiepileptic therapy, actually proposed also for migraine therapy.

CholesterolEpilepsyFree fatty acidCholesterol; Epilepsy; Free fatty acids; ketogenic diet; Medicine (all)ketogenic dietMedicine (all)
researchProduct

Ketogenic diet as antiepileptic therapy: Administration and formulas

2017

In 1921 Wilder defined classical cholesterol diet providing the patient with a daily calorie intake of less than 20% compared to age-related requirements. The main macronutrient is represented by saturated and long chain unsaturated fatty acids, in the ratio of 4: 1 to carbohydrates and proteins (4 grams of lipids per gram of carbohydrates and proteins). One of the first therapeutic protocols proposed is that of John Hopkins that the onset of the diet should take place in a hospital environment to assess the patient's response in a controlled situation.

CholesterolEpilepsyFree fatty acidMedicine (all)AdministrationFormulaKetogenic dietAdministration; Cholesterol; Epilepsy; Formulas; Free fatty acids; Ketogenic diet; Medicine (all)
researchProduct

Metabolic Consequences of Obstructive Sleep Apnea

2022

The effects of OSA on metabolism are quite complex, and obesity, diabetes, nonalcoholic fatty liver disease and dyslipidemia often coexist with OSA, making it difficult to tease out the independent effects of OSA on metabolic variables. There is firm experimental evidence of a detrimental impact of OSA on adipose tissue dysfunction, with intermittent hypoxia, sympathetic hyperactivity, and oxidative stress as the most important intermediate mechanisms. Sleep fragmentation or deprivation may also contribute to the metabolic dysfunction of OSA. This work reviews the current knowledge on this topic, as well as the results of studies on the effects of CPAP treatment.

InflammationDiabetes mellitu...CholesterolFree fatty acidInsulin resistanceContinuous positive airway pressure (CPAP)Settore MED/10 - Malattie Dell'Apparato RespiratorioCardiovascular riskMetabolic syndromeNonalcoholic fatty liver disease (NAFLD)
researchProduct

Induction of the fatty acid transport protein 1 and acyl-CoA synthase genes by dimer-selective rexinoids suggests that the peroxisome proliferator-ac…

2000

The intracellular fatty acid content of insulin-sensitive target tissues determines in part their insulin sensitivity. Uptake of fatty acids into cells is a controlled process determined in part by a regulated import/export system that is controlled at least by two key groups of proteins, i.e. the fatty acid transport protein (FATP) and acyl-CoA synthetase (ACS), which facilitate, respectively, the transport of fatty acids across the cell membrane and catalyze their esterification to prevent their efflux. Previously it was shown that the expression of the FATP-1 and ACS genes was controlled by insulin and by peroxisome proliferator-activated receptor (PPAR) agonists in liver or in adipose t…

MalePeroxisome proliferator-activated receptor gammaTime FactorsReceptors Retinoic AcidRetinoic acidReceptors Cytoplasmic and NuclearPeroxisome proliferator-activated receptorTretinoinRetinoid X receptorBiologyFatty Acid-Binding ProteinsBiochemistryMicechemistry.chemical_compoundCoenzyme A LigasesTumor Cells CulturedAnimalsHumansTissue DistributionMolecular BiologyNucleic Acid Synthesis InhibitorsCell Nucleuschemistry.chemical_classificationDose-Response Relationship DrugFatty AcidsMembrane ProteinsFatty acidMembrane Transport ProteinsSerum Albumin Bovine3T3 CellsCell BiologyFatty Acid Transport ProteinsRatsRats ZuckerRetinoic acid receptorRetinoid X ReceptorschemistryBiochemistryDactinomycinFree fatty acid receptorRNAPeroxisome proliferator-activated receptor alphaCaco-2 CellsCarrier ProteinsTranscription Factors
researchProduct